Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on I 7 years of follow-up from CheckMate 025 trial.-MedSci.cn

Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on I 7 years of follow-up from CheckMate 025 trial.

George, S; Larkin, J; Chepynoga, K; Sharpe, D; De, T; Dyer, M; Ejzykowicz, F; May, J; Kurt, M

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 ():

科室
- - 订阅+
  - 更多科室
工具
服务